Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1282-1291

  Zeuzem, Stefan ^a   Soriano, Vicente ^b   Asselah, Tarik ^c   Gane, Edward J ^d   Bronowicki, Jean Pierre ^e   Angus, Peter ^f   Lohse, Ansgar W ^g   Stickel, Felix ^h   Müllhaupt, Beat ⁱ   Roberts, Stuart ^j   Schuchmann, Marcus ^k   Manns, Michael ^l   Bourlière, Marc ^m   Buti, Maria ⁿ   Stern, Jerry O ^o   Gallivan, John Paul ^p   Voss, Florian ^p   Sabo, John P ^o   Böcher, Wulf ^p   Mensa, Federico J ^o  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c BEAUJON HOSPITAL   (France)

^d Auckland Clinical Studies   (New Zealand)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f AUSTIN HEALTH   (Australia)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j ALFRED HOSPITAL   (Australia)

^k UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m HÔPITAL SAINT JOSEPH   (France)

ⁿ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^o BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^p BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; DELEOBUVIR; FALDAPREVIR; HEMOGLOBIN; RIBAVIRIN; VIRUS RNA; ACRYLIC ACID DERIVATIVE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; N-((CYCLOPENTYLOXY)CARBONYL)-3-METHYLVALYL-4-((8-BROMO-7-METHOXY-2-(2-((2-METHYLPROPANOYL)AMINO)-1,3-THIAZOL-4-YL)QUINOLIN-4-YL)OXY)-N-(1-CARBOXY-2-ETHENYLCYCLOPROPYL)PROLINAMIDE; OLIGOPEPTIDE; THIAZOLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELASTOGRAPH; EOSINOPHILIA; ERYTHEMA MULTIFORME; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THROMBOPHILIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; VIRUS DETECTION; VOMITING; COMPLICATION; HEPATITIS C, CHRONIC; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ACRYLATES; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OLIGOPEPTIDES; RIBAVIRIN; THIAZOLES; YOUNG ADULT;

EID: 84921909959     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04383-14     Document Type: Article

References (34)

1. European Association of the Study of the Liver. 2012. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 32(Suppl 1):2-8. http://dx.doi.org/10.1111/j.1478 -3231.2011.02703.x.
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. 2011. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433-1444. http://dx.doi.org/10.1002 /hep.24641.
3. Alazawi W, Cunningham M, Dearden J, Foster GR. 2010. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 32:344-355. http://dx.doi.org/10.1111 /j.1365-2036.2010.04370.x.
4. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE. 2011. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 54:396-405. http://dx.doi.org/10.1002/hep.24370.
5. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. 2010. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 16:748-759. http://dx.doi.org/10 .1002/lt.22072.
6. Everson GT, Balart L, Lee SS, Reindollar RW, Shiffman ML, Minuk GY, Pockros PJ, Govindarajan S, Lentz E, Heathcote EJ. 2008. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 27:542-551. http://dx.doi.org/10.1111/j.1365 -2036.2008.03620.x.
7. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL. 2007. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45:579-587. http://dx.doi.org/10.1002/hep.21492.
8. Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P. 2010. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 51:388-397. http://dx.doi.org/10.1002/hep.23340.
9. Aghemo A, Rumi MG, Monico S, Prati GM, D'Ambrosio R, Donato MF, Colombo M. 2009. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antivir Ther 14:577-584.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-1374. http://dx.doi.org/10.1002/hep.22759.
11. Vertex Pharmaceuticals Inc. 2013. Incivek (telaprevir) prescribing information. Vertex Pharmaceuticals Inc., Cambridge, MA. http://www .accessdata.fda.gov/drugsatfda-docs/label/2013/201917s012lbl.pdf. Accessed 15 July 2014.
12. Merck & Co., Inc. 2014. Victrelis (boceprevir) prescribing information. Merck Sharp & Dohme Corp., Whitehouse Station, NJ. http://www.access data.fda.gov/drugsatfda-docs/label/2014/202258s014lbl.pdf. Accessed 15 July 2014.
13. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195-1206. http://dx.doi.org/10.1056/NEJMoa1010494.
14. Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH. 2013. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol 58:479-487. http://dx.doi.org/10 .1016/j.jhep.2012.11.020.
15. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207-1217. http: //dx.doi.org/10.1056/NEJMoa1009482.
16. Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, DiNubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S. 2013. Abstract 1430. Safety and efficacy of boceprevir/peginterferon/ ribavirin (BOC/P/R) combination therapy for chronic HCV G1 patients with compensated cirrhosis: a meta-analysis of five phase 3 clinical trials. J Hepatol 58 (Suppl 1) : S576-S577. http://dx.doi.org/10.1016 /S0168-8278(13)61429-4.
17. Pol S, Roberts S, Andreone P, Younossi Z, Diago M, Lawitz EJ, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, DeMasi R, van Heeswijk R, De Meyer S, Picchio G, Witek J, Zeuzem S. 2011. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase 3 study, abstr 31. Hepatology 54(Suppl 1) :374A-375A.
18. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. 2013. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 59: 434-441. http://dx.doi.org/10.1016/j.jhep.2013.04.035.
19. Janssen Therapeutics. 2013. Olysio (simeprevir) prescribing information. Janssen Therapeutics, Titusville, NJ. http://www.accessdata.fda.gov /drugsatfda-docs/label/2013/205123s001lbl.pdf. Accessed 15 July 2014.
20. Gilead Sciences Inc. 2013. Sovaldi (sofosbuvir) prescribing information. Gilead Sciences Inc., Foster City, CA. http://www.accessdata.fda.gov /drugsatfda-docs/label/2013/204671s000lbl.pdf. Accessed 15 July 2014.
21. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368:1878-1887. http: //dx.doi.org/10.1056/NEJMoa1214853.
22. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. 2014. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, pla-cebo-controlled phase 3 trial. Lancet 384: 414-426. http://dx.doi.org /10.1016/S0140-6736(14)60538-9.
23. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. 2014. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treat-ment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebocontrolled trial. Lancet 384: 403- 413. http://dx.doi.org/10.1016/S0140 -6736(14)60494-3.
24. Jacobson IM, Dore GJ, Foster GR, Fried MW, Manns MP, Marcellin P, Poordad F, Araujo ES, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. 2013. Poster 1122. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials. Hepatology 58:730A-760A. http://dx.doi.org/10.1002/hep.26858.
25. White PW, Llinas-Brunet M, Amad M, Bethell RC, Bolger G, Cordingley MG, Duan J, Garneau M, Lagace L, Thibeault D, Kukolj G. 2010. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 54:4611-4618. http://dx.doi.org/10.1128/AAC.00787-10.
26. Manns MP, Bourliere M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D, Berg T, Calleja JL, White PW, Stern JO, Steinmann G, Yong CL, Kukolj G, Scherer J, Boecher WO. 2011. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 54:1114-1122. http://dx .doi.org/10.1016/j.jhep.2010.08.040.
27. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Bocher WO, Mensa FJ. 2013. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 369:630-639. http://dx.doi.org/10.1056/NEJMoa1213557.
28. Zeuzem S, Dufour JF, Buti M, Soriano V, Buynak RJ, Mantry P, Taunk J, Stern JO, Vinisko R, Gallivan JP, Bocher W, Mensa FJ, SOUND-C3 Study Group. 16 October 2014. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a phase 2b study. Liver Int http://dx.doi.org/10.1111/liv.12693.
29. Larrey D, Benhamou Y, Lohse AW, Trepo C, Mölleken C, Bronowicki JP, Heim M, Arasteh K, Zarski JP, Bourlière M, Wiest R, Calleja JL, Enriquez J, Erhardt A, Wedemeyer H, Gerlach T, Berg T, Stern J, Wu K, Abdallah N, Nehmiz G, Boecher W, Berger F, Steffgen J. 2009. BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C, poster 1599. Hepatology 50(Suppl 4):267A.
30. Beaulieu PL, Anderson PC, Brochu C, Bos M, Cordingley M, Duan J, Garneau M, Lagrace L, Marquis M, McKercher G, Poupart B, Rancourt J, Stammers T, Tsantrizos YS, Kukolj G. 2012. Abstract 822. Preclinical characterization of the hepatitis C virus NS5B polymerase non-nucleoside inhibitor BI 207127. J Hepatol 56(Suppl 2):S321. http://dx.doi.org/10 .1016/S0168-8278(12)60834-4.
31. Sane RS, Steinmann GG, Huang Q, Li Y, Podila L, Mease K, Olson S, Taub ME, Stern JO, Nehmiz G, Bocher WO, Asselah T, Tweedie D. 2014. Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients. J Pharmacol Exp Ther 351:403-412. http://dx.doi.org/10 .1124/jpet.114.218081.
32. Cooper C, Conway B, Ghesquiere W, Lalonde R, Ramji A, Chandok N, Tam E, Sane R, Ting N, Mensa FJ, Elgadi M, Sabo JP. 2013. Poster 1083. Pharmacokinetic interactions of faldaprevir and deleobuvir (BI 207127) and their individual and combined effect on selected cytochrome P450 (CYP) probe substrates in genotype 1 hepatitis C infected patients. Hepatology 58:730A-760A. http://dx.doi.org/10.1002/hep.26858.
33. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Brau N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. 2014. Ledipasvir and sofosbuvir for untreatedHCVgenotype 1 infection.NEngl J Med 370:1889-1898. http://dx.doi.org/10.1056/NEJMoa1402454.
34. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. 2014. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370:1273-1982. http://dx.doi.org /10.1056/NEJMoa1402869.